Medicenna Therapeutics Depreciation & Amortization Growth & History (MDNAF)
Medicenna Therapeutics's depreciation and amortization was $72,000 for fiscal 2026.
View full Medicenna Therapeutics company overviewMedicenna Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $72,000 | $19,000 | +35.85% |
| 2025 | 2025-03-31 | $53,000 | $49,000 | +1225.00% |
| 2024 | 2024-03-31 | $4,000 | −$1,000 | −20.00% |
| 2023 | 2023-03-31 | $5,000 | −$32,000 | −86.49% |
| 2022 | 2022-03-31 | $37,000 | −$3,000 | −7.50% |
| 2021 | 2021-03-31 | $40,000 | $32,000 | +400.00% |
| 2020 | 2020-03-31 | $8,000 | — | — |
Medicenna Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $17,000 | −$2,000 | −10.53% |
| Q4 2026 | 2026-03-31 | $14,000 | −$5,000 | −26.32% |
| Q3 2026 | 2025-12-31 | $16,000 | — | — |
| Q2 2026 | 2025-09-30 | $23,000 | — | — |
| Q1 2026 | 2025-06-30 | $19,000 | — | — |
| Q4 2025 | 2025-03-31 | $19,000 | — | — |
Medicenna Therapeutics depreciation and amortization trends
Over the last five fiscal years, Medicenna Therapeutics's depreciation and amortization increased from $40,000 to $72,000, a change of $32,000. The latest reported quarter, Q1 2027, shows $17,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medicenna Therapeutics source filings ↗